NCT05881525View on ClinicalTrials.gov

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

TC-N201 cells

T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.

DRUG

IL-2

Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Cyclophosphamide

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Nab-paclitaxel

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Trial Locations (1)

Unknown

RECRUITING

TCRCure Biopharma Ltd., Chongqing

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

TCRCure Biopharma Ltd.

INDUSTRY